Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patient preferences for adjuvant interferon alfa-2b treatment.
Kilbridge KL, Weeks JC, Sober AJ, Haluska FG, Slingluff CL, Atkins MB, Sock DE, Kirkwood JM, Nease RF. Kilbridge KL, et al. Among authors: haluska fg. J Clin Oncol. 2001 Feb 1;19(3):812-23. doi: 10.1200/JCO.2001.19.3.812. J Clin Oncol. 2001. PMID: 11157035
Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.
Mitchell MS, Abrams J, Thompson JA, Kashani-Sabet M, DeConti RC, Hwu WJ, Atkins MB, Whitman E, Ernstoff MS, Haluska FG, Jakowatz JG, Das Gupta TK, Richards JM, Samlowski WE, Costanzi JJ, Aronson FR, Deisseroth AB, Dudek AZ, Jones VE. Mitchell MS, et al. Among authors: haluska fg. J Clin Oncol. 2007 May 20;25(15):2078-85. doi: 10.1200/JCO.2006.10.1709. J Clin Oncol. 2007. PMID: 17513813 Clinical Trial.
Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.
Flaherty LE, Othus M, Atkins MB, Tuthill RJ, Thompson JA, Vetto JT, Haluska FG, Pappo AS, Sosman JA, Redman BG, Moon J, Ribas A, Kirkwood JM, Sondak VK. Flaherty LE, et al. Among authors: haluska fg. J Clin Oncol. 2014 Nov 20;32(33):3771-8. doi: 10.1200/JCO.2013.53.1590. Epub 2014 Oct 20. J Clin Oncol. 2014. PMID: 25332243 Free PMC article. Clinical Trial.
Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma.
Jonasch E, Kumar UN, Linette GP, Hodi FS, Soiffer RJ, Ryan BF, Sober AJ, Mihm MC, Tsao H, Langley RG, Cosimi BA, Gadd MA, Tanabe KK, Souba W, Haynes HA, Barnhill R, Osteen R, Haluska FG. Jonasch E, et al. Among authors: haluska fg. Cancer J. 2000 May-Jun;6(3):139-45. Cancer J. 2000. PMID: 10882328 Clinical Trial.
Innovations and challenges in melanoma: summary statement from the first Cambridge conference.
Atkins MB, Elder DE, Essner R, Flaherty KT, Gajewski TF, Haluska FG, Hwu P, Keilholz U, Kirkwood JM, Mier JW, Ross MI, Slingluff CL, Sondak VK, Sosman JA, Weinstock MA, King L. Atkins MB, et al. Among authors: haluska fg. Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2291s-2296s. doi: 10.1158/1078-0432.CCR-05-2560. Clin Cancer Res. 2006. PMID: 16609047
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG; Oblimersen Melanoma Study Group. Bedikian AY, et al. Among authors: haluska fg. J Clin Oncol. 2006 Oct 10;24(29):4738-45. doi: 10.1200/JCO.2006.06.0483. Epub 2006 Sep 11. J Clin Oncol. 2006. PMID: 16966688 Clinical Trial.
Adjuvant interferon for stage II melanoma.
Haluska FG. Haluska FG. J Clin Oncol. 1998 Sep;16(9):3205-6. doi: 10.1200/JCO.1998.16.9.3205. J Clin Oncol. 1998. PMID: 9738597 No abstract available.
102 results